Oxiracetam.

Oxiracetam raises cholinergic and glutamatergic activity, which draws on the free choline available for acetylcholine synthesis. Alpha-GPC crosses the blood brain barrier and refills that pool, which is why it is the standard companion.

Acetylcholine output is limited by choline reaching the nerve terminal. Raising turnover without raising the precursor is the usual reason a racetam session ends with a dull head.

Oxiracetam is a hydroxylated piracetam analogue and the two have been studied side by side on the same AMPA and cholinergic measures. They overlap rather than complement, and the combined choline demand is additive.

Huperzine A slows the enzyme that clears acetylcholine while oxiracetam raises its release and receptor response. The cholinergic effect is additive, so both at full dose is easy to overshoot.

Acetylcholine needs an acetyl group as well as choline, and acetyl-L-carnitine can supply it through acetyl-CoA. It also carries fatty acid substrate into mitochondria for the energy the synapse uses.

Phosphatidylserine is a structural component of neuronal membranes and influences how receptors and vesicle release machinery sit in them. It supports the surface oxiracetam acts on rather than the transmitter itself.

Noopept is a dipeptide relative of the racetam series acting on similar glutamatergic and cholinergic measures. Combining the two repeats one mechanism and adds to the same choline demand.

Citicoline delivers both choline and cytidine, feeding phosphatidylcholine synthesis and the free choline pool that choline acetyltransferase draws on for acetylcholine. Racetam-class compounds are described in the literature as increasing cholinergic demand, which is why choline donors are the standard co-ingredient. The pathway is textbook; the pairing has not been trialled as a combination.

Phosphatidylcholine is hydrolysed by phospholipases to release choline, and it is also the structural bulk of neuronal membranes. It supplies the same substrate as citicoline by a slower route. Bulk lecithin-derived material contains only a fraction phosphatidylcholine, so the label figure matters.

Lecithin is a phospholipid mixture in which phosphatidylcholine is one component alongside phosphatidylethanolamine and phosphatidylinositol. It is a choline source at a lower concentration than purified phosphatidylcholine or citicoline. Sunflower-derived material avoids the soy allergen question.

Pantothenate is the obligatory precursor of coenzyme A, and acetyl-CoA is the acetyl donor that choline acetyltransferase uses to make acetylcholine. Choline alone cannot become acetylcholine without it. This is settled cofactor biochemistry and needs no combination study to state.

Theanine raises alpha-band EEG activity and is studied on subjective calm under cognitive load, which is the opposite direction from the overstimulation and headache some users report with racetam stacks. That makes it a smoothing partner rather than an amplifying one. Both literatures are separate and the combination is unstudied.

Caffeine antagonises A1 and A2A adenosine receptors, producing arousal on a same-dose timescale. Stacked with a stimulating racetam it can add to jitteriness and interfere with sleep. The interaction is additive on the arousal axis and is a titration question rather than a benefit.

Magnesium occupies the NMDA receptor channel as a voltage-dependent block and is the counter-ion for ATP in every kinase step. Racetam-class compounds are described as modulating glutamatergic signalling, so magnesium sits on the same receptor system from the opposite side. Adequate magnesium is a physiological baseline rather than a stack add-on.

Taurine is a weak agonist at glycine and GABA-A receptors and a major intracellular osmolyte in excitable tissue. In a stimulating stack it contributes on the inhibitory side. Settled neurochemistry, no combination data with this compound.

Creatine kinase and the phosphocreatine pool buffer ATP regeneration in brain as well as muscle, which is a cellular energetics contribution rather than a receptor one. It is one of the few nootropic-adjacent ingredients with human cognitive data in its own right. The mechanism is textbook; nothing here describes the combination.

DHA is the dominant polyunsaturated fatty acid of neuronal and synaptic membranes, and membrane composition affects receptor and channel behaviour. Supplying membrane material is a different layer from modulating a receptor. This describes composition, not an effect.

DHA is enriched in synaptic membrane phospholipids and in phosphatidylethanolamine and phosphatidylserine specifically. Where a stack also supplies choline donors, the two feed the same membrane phospholipid pool from the head-group and the acyl-chain side. Straightforward biochemistry, no combination data.

Methylcobalamin is the cofactor for methionine synthase, which regenerates methionine and therefore S-adenosylmethionine, the methyl donor used to make phosphatidylcholine from phosphatidylethanolamine. Choline supply and methylation capacity are linked pathways. Cofactor relationships of this kind are settled and need no citation.

5-methyltetrahydrofolate donates its methyl group to homocysteine through methionine synthase, feeding the same S-adenosylmethionine pool that supports phospholipid methylation and monoamine metabolism. Folate and B12 are interdependent at that single step. Textbook one-carbon chemistry.

Pyridoxal 5-phosphate is the cofactor for aromatic L-amino acid decarboxylase and glutamate decarboxylase, so it sits on the synthesis of dopamine, serotonin and GABA. It also feeds the transsulfuration arm of homocysteine handling. Established cofactor chemistry, relevant to any stack aimed at neurotransmitter systems.

Tyrosine is hydroxylated by tyrosine hydroxylase to L-DOPA and then decarboxylated to dopamine, the rate-limiting entry to the catecholamine pathway. Precursor supply matters most when catecholamine turnover is high, which is the situation tyrosine studies are usually built around. Supplying precursor is not the same as raising transmitter release.

Bacosides are studied over eight to twelve weeks on memory acquisition and retention measures, an accumulation profile unlike an acute synthetic compound. Stacking gives a slow and a fast ingredient. Bacopa also commonly causes gastrointestinal upset when taken without food, which is the practical trade-off.

Hericenones and erinacines are studied for neurotrophic signalling rather than for receptor or cholinergic effects, so the mechanisms do not overlap with a racetam. That is why the two appear in the same stacks. No combination evidence exists, and the mushroom's compound content depends heavily on extraction method.

Standardised ginkgo extracts act on cerebral perfusion measures and antagonise platelet-activating factor. The perfusion angle is unrelated to cholinergic or glutamatergic modulation. The platelet-activating factor effect is the reason ginkgo needs a clinician conversation for anyone on antiplatelet or anticoagulant therapy.

Rosavins and salidroside are studied on mental fatigue and workload measures rather than on memory consolidation. Stacked with a stimulating synthetic compound, both push on arousal, so the additive direction is worth naming. Extract standardisation to rosavin and salidroside percentages is what makes doses comparable.

Withanolides are studied on cortisol measures and stress-axis tone, which is a damping direction in a stack that is otherwise stimulating. Cortisol is a marker and a change in it is not itself an outcome. Ashwagandha is also mildly sedating for some users, which is the relevant trade-off with a daytime stack.

Melatonin acts at MT1 and MT2 receptors to shift circadian phase, and memory consolidation depends on sleep architecture. A stimulating daytime compound that disturbs sleep undoes part of what it was taken for, which is why sleep timing is the relevant lever. Melatonin's effect depends strongly on when in the day it is taken.

Nicotinamide riboside is converted to NAD+ through NRK phosphorylation and NMNAT adenylylation, bypassing the NAMPT bottleneck. NAD+ is required for glycolytic and mitochondrial electron transfer, so it sits on the energetics side of a cognition stack. Rising blood NAD+ metabolites is a measured marker, not an outcome.

Ubiquinone carries electrons from complexes I and II to complex III and is also a lipid-phase antioxidant. That places it on cellular energy supply rather than on synaptic signalling. Absorption is fat-dependent, so it belongs with a meal.

Carnitine shuttles long-chain fatty acids across the inner mitochondrial membrane through the CPT1 and CPT2 system, which is how those fats reach beta-oxidation. It is the energetics complement to the acetyl-donor role of its acetylated form. Plain L-carnitine crosses into the brain far less readily than the acetyl ester.